Pharmaceutical Executive-10-01-2006

Pharmaceutical Executive

Back Page: Pharma's Mega-Brands

October 01, 2006

Column

0

0

Almost $60 billion of the drug industry's global sales comes from just 10 drugs. In fact, these so-called "mega-brands" have sales so high that they are bigger than many Fortune 500 companies. So why aren't they being managed that way?

Direct to Consumer: If These Walls Had Ears

October 01, 2006

Column

0

0

Dtc advertising has caused more than its share of controversy both inside and outside the industry. Critics wonder: Are patients paying for drugs they don't need? Meanwhile, industry is still struggling to answer the basics: How effective is DTC in getting patients to request a drug by name? CommonHealth's MBS/Vox division conducted a survey that tried to answer industry's question, and in doing so, inform the wider debate about DTC's role in healthcare.

From the Editor: In Conflict

October 01, 2006

From the Editor

0

0

The problem isn't that there's conflict between safety and efficacy or between getting a useful medicine to market and protecting the public from a dangerous one. The problem is that the conflict isn't well structured. That needs to change.

Sales and Marketing: Where the Buck Stops

October 01, 2006

Features

0

0

Cost-shifting is still one of the favorite tools in almost all employers' cost-cutting toolboxes. But many fear that shifting too many costs to workers will backfire. Low co-pays keep people healthy and on the job: a big return on investment.

Smaller is Better

October 01, 2006

Features

0

0

New partnerships with nanobiotech firms are helping pharma companies overcome solubility problems and extend profitable product lifecycles.

China: Big Rewards. Bigger Risks?

October 01, 2006

Features

0

0

As pharmaceutical markets go, china is a land of opportunity fraught with complex challenges. Potentially the world's largest market for prescription drugs, China is also the fastest growing market among large countries. At the same time, the sprawling system of 17,000 hospitals-the most important drug-distribution channel in China-is fragmented and encumbered by Byzantine regulations.

Legal: Going to Court

October 01, 2006

Legal

0

0

In cases that reached a verdict between 2002 and 2006, the branded pharma industry won six of six cases by verdict in Delaware, but lost six of eight in New Jersey, all by summary judgement. Despite what judges say, it's no coincidence.

"I Pray for the Welfare of Your Company..."

October 01, 2006

Executive Profile

0

0

Isr?l makov has adventure in his blood. A fourth-generation Isr?li, he speaks proudly of his great grandmother, who bought and sold wool in Russia until the late 1890s when, at the age of 50, she moved to Palestine, bought a piece of land, and helped found a town in the wilderness. It was the kind of career move that Makov, CEO of Teva Pharmaceuticals, admires and emulates. As a boy, he rode a donkey to work in his father's orchards on the land his great grandmother bought. He attended an agricultural boarding school, started his career in citrus exports and-decades before Teva recruited him-managed Abic, the second-largest pharma company in Isr?l, and founded Interpharm, the country's first biotech company.

Back to the Future?

October 01, 2006

Features

0

0

A sales rep's sensitivity to the doctor's marketplace, and his understanding of the pressures on physicians-from formularies and HMO rules to the practices of affiliate hospitals-makes him a greater asset in the customer's eyes. Getting to know a doctor involves understanding the responsibilities of personnel in his office. Reps need to know who the doctor relies on most to get things done.

Learn & Confirm

October 01, 2006

Features

0

0

In revamping its R&D department, Wyeth "really looked for people who were not going to give us the same old, 'This is how you do pharmaceutical development, dah-dah-dah,' but who could really think of different ways of doing things."

Thoughtleader: Rob Scott, AtheroGenics

October 01, 2006

Thought Leader

0

0

With "launched the world's best-selling drug" on his resume, Rob Scott was ready for his next professional endeavour. The former Pfizer executive is now head of R&D and chief medical officer at AtheroGenics, named for the signature technology that's being used to develop AGI-1067, a cardiovascular anti-inflammatory in late Phase III clinical trials.